Malta - enska - Malta Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - sodium hydrogen, carbonate, sodium lactate, calcium chloride, glucose monohydrate, magnesium chloride, hexahydrate, sodium chloride - solution for peritoneal dialysis - sodium hydrogen carbonate 2.1 g/l sodium lactate 1.68 g/l calcium chloride 0.184 g/l glucose monohydrate 42.5 g/l magnesium chloride hexahydrate 0.051 g/l sodium chloride 5.38 g/l - blood substitutes and perfusion solutions

Malta - enska - Malta Medicines Authority

baxter healthcare limited - calcium chloride; aprotinin; fibrinogen, human; thrombin, human - solution for sealant - calcium chloride 40 µmole/ml; aprotinin 3000 kiu/ml; fibrinogen, human 91 mg/ml; thrombin, human 500 iu/mg - antihemorrhagics

Malta - enska - Malta Medicines Authority

baxter healthcare limited - human fibrinogen; aprotinin; human thrombin; calcium chloride dihydrate - solution for sealant - human fibrinogen 455 mg; aprotinin 1500 kiu/ml; human thrombin 2500 iu; calcium chloride dihydrate 200 mmol - antihemorrhagics

Malta - enska - Malta Medicines Authority

baxter healthcare limited - human fibrinogen; aprotinin; human thrombin; calcium chloride dihydrate - solution for sealant - human fibrinogen 182 mg; aprotinin 6000 kiu/ml; human thrombin 1000 iu; calcium chloride dihydrate 80 µmol - antihemorrhagics

Írland - enska - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human fibrinogen; human thrombin; calcium chloride; aprotinin - solution for sealant - 4 ml - local hemostatics; tissue adhesives

Írland - enska - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - human fibrinogen; human thrombin; calcium chloride; aprotinin - solution for sealant - 4 ml - local hemostatics; tissue adhesives

Írland - enska - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - human fibrinogen; aprotinin; human factor xiii; human thrombin; calcium chloride - solution for sealant - . - local hemostatics; tissue adhesives

Írland - enska - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - human fibrinogen; aprotinin; human factor xiii; human thrombin; calcium chloride - solution for sealant - . - local hemostatics; tissue adhesives

Bandaríkin - enska - NLM (National Library of Medicine)

baxter healthcare corporation - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 90 mg in 1 ml - hemostasis: tisseel is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. tisseel is effective in heparinized patients. sealing: tisseel is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. do not inject tisseel directly into the circulatory system or into highly vascularized tissue. intravascular application of tisseel can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients ( see warnings and precautions (5.3 ) and adverse reactions (6.2) ). do not use tisseel in individuals with a known hypersensitivity to aproti

Bandaríkin - enska - NLM (National Library of Medicine)

csl behring gmbh - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 1300 mg in 50 ml - riastap® , fibrinogen concentrate (human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. limitation of use riastap is not indicated for dysfibrinogenemia. riastap is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products. risk summary there are no studies of riastap use in pregnant women. animal reproduction studies have not been conducted with riastap. it is not known whether riastap can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the presence of riastap in human milk, its effects on the breastfed infant, or its effects on mi